MicroRNA-133b inhibits the migration and invasion of non small cell lung cancer cells via targeting FSCN1 Retraction in /10.3892/ol.2021.12929

Yang,Xucheng; Lei,Pengfei; Huang,Yong; Zhang,Zijian; Zhang,Yingying

doi:10.3892/ol.2016.5044

MicroRNA-133b inhibits the migration and invasion of non small cell lung cancer cells via targeting FSCN1

Retraction in: /10.3892/ol.2021.12929

Authors:
- Xucheng Yang
- Pengfei Lei
- Yong Huang
- Zijian Zhang
- Yingying Zhang
View Affiliations

Affiliations: Department of Orthopedics, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China, Department of Oncology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China
Published online on: August 25, 2016 https://doi.org/10.3892/ol.2016.5044
Pages: 3619-3625

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)-133b has been reported to act as a tumor suppressor in multiple types of human cancers, including non small cell lung cancer (NSCLC). However, the underlying mechanism by which miR‑133b inhibits NSCLC metastasis remains largely unclear. In the present study, reverse transcription‑quantitative polymerase chain reaction and western blotting were used to detect messenger RNA and protein expression. A wound healing assay and transwell assay were used to examine the cell migration and invasion. The expression level of miR‑133b was found to be significantly downregulated in NSCLC cell lines compared with normal lung epithelial BEAS‑2B cells. Further investigation identified fascin1 (FSCN1) as a direct target of miR‑133b in NSCLC cells. The expression of FSCN1 was significantly increased in NSCLC cell lines compared with BEAS‑2B cells, and its protein expression was negatively regulated by miR‑133b in NSCLC A549 cells. Further investigation showed that the upregulation of miR‑133b notably inhibited NSCLC cell migration and invasion, while the overexpression of FSCN1 significantly promoted NSCLC cell migration and invasion. Furthermore, the overexpression of FSCN1 reversed the suppressive effect of miR‑133b overexpression on NSCLC cell migration and invasion. Accordingly, the present study suggests that miR‑133b inhibits the migration and invasion of NSCLC cells via directly targeting FSCN1, and thus may be used for the treatment of NSCLC metastasis.

View Figures

View References

1	DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014. View Article : Google Scholar : PubMed/NCBI
2	Dimou A and Papadimitrakopoulou V: Non-small cell lung cancer beyond biomarkers: The evolving landscape of clinical trial design. J Pers Med. 4:386–401. 2014. View Article : Google Scholar : PubMed/NCBI
3	Chouaid C, Crequit P, Borget I and Vergnenegre A: Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: A systematic review. Clinicoecon Outcomes Res. 7:9–15. 2014. View Article : Google Scholar : PubMed/NCBI
4	Landi L and Cappuzzo F: Pharmacotherapy targeting the EGFR oncogene in NSCLC. Expert Opin Pharmacother. 15:2293–2305. 2014. View Article : Google Scholar : PubMed/NCBI
5	Domvri K, Zarogoulidis P, Darwiche K, Browning RF, Li Q, Turner JF, Kioumis I, Spyratos D, Porpodis K, Papaiwannou A, et al: Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy. J Cancer. 4:736–754. 2013. View Article : Google Scholar : PubMed/NCBI
6	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
7	Li J, Song Y, Wang Y, Luo J and Yu W: MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. Mol Cell Biochem. 380:277–282. 2013. View Article : Google Scholar : PubMed/NCBI
8	Jiang M, Zhang P, Hu G, Xiao Z, Xu F, Zhong T, Huang F, Kuang H and Zhang W: Relative expressions of miR-205-5p, miR-205-3p and miR-21 in tissues and serum of non-small cell lung cancer patients. Mol Cell Biochem. 383:67–75. 2013. View Article : Google Scholar : PubMed/NCBI
9	Liu L, Shao X, Gao W, Zhang Z, Liu P, Wang R, Huang P, Yin Y and Shu Y: MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor. FEBS J. 279:3800–3812. 2012. View Article : Google Scholar : PubMed/NCBI
10	Zheng K, Liu W, Liu Y, Jiang C and Qian Q: MicroRNA-133a suppresses colorectal cancer cell invasion by targeting Fascin1. Oncol Lett. 9:869–874. 2015.PubMed/NCBI
11	Zhao J, Zhou Y, Zhang Z, Tian F, Ma N, Liu T, Gu Z and Wang Y: Upregulated fascin1 in non-small cell lung cancer promotes the migration and invasiveness, but not proliferation. Cancer Lett. 290:238–247. 2010. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Boon RA and Vickers KC: Intercellular transport of microRNAs. Arterioscler Thromb Vasc Biol. 33:186–192. 2013. View Article : Google Scholar : PubMed/NCBI
14	Liu X, Yan S, Pei C and Cui Y: Decreased microRNA-132 and its function in human non-small cell lung cancer. Mol Med Rep. 11:3601–3608. 2015.PubMed/NCBI
15	Liu MX, Zhou KC and Cao Y: MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer. Mol Cancer. 13:2452014. View Article : Google Scholar : PubMed/NCBI
16	Campayo M, Navarro A, Vinolas N, Diaz T, Tejero R, Gimferrer JM, Molins L, Cabanas ML, Ramirez J, Monzo M and Marrades R: Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer. Eur Respir J. 41:1172–1178. 2013. View Article : Google Scholar : PubMed/NCBI
17	Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A and Hu J: MiRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res. 29:1512010. View Article : Google Scholar : PubMed/NCBI
18	Crawford M, Batte K, Yu L, Wu X, Nuovo GJ, Marsh CB, Otterson GA and Nana-Sinkam SP: MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun. 388:483–489. 2009. View Article : Google Scholar : PubMed/NCBI
19	Chen XN, Wang KF, Xu ZQ, Li SJ, Liu Q, Fu DH, Wang X and Wu B: MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1. Cancer Cell Int. 14:702014. View Article : Google Scholar : PubMed/NCBI
20	Wang J, Li Y and Jiang C: MiR-133b contributes to arsenic-induced apoptosis in U251 glioma cells by targeting the hERG channel. J Mol Neurosci. 55:985–994. 2015. View Article : Google Scholar : PubMed/NCBI
21	Wu Y, Crawford M, Yu B, Mao Y, Nana-Sinkam SP and Lee LJ: MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm. 8:1381–1389. 2011. View Article : Google Scholar : PubMed/NCBI
22	Park SH, Song JY, Kim YK, Heo JH, Kang H, Kim G, An HJ and Kim TH: Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells. Int J Oncol. 44:637–646. 2014.PubMed/NCBI
23	Guo L, Bai H, Zou D, Hong T, Liu J, Huang J, He P, Zhou Q and He J: The role of microRNA-133b and its target gene FSCN1 in gastric cancer. J Exp Clin Cancer Res. 33:992014. View Article : Google Scholar : PubMed/NCBI
24	Hwang JH, Smith CA, Salhia B and Rutka JT: The role of fascin in the migration and invasiveness of malignant glioma cells. Neoplasia. 10:149–159. 2008. View Article : Google Scholar : PubMed/NCBI
25	Al-Alwan M, Olabi S, Ghebeh H, Barhoush E, Tulbah A, Al-Tweigeri T, Ajarim D and Adra C: Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS One. 6:e273392011. View Article : Google Scholar : PubMed/NCBI
26	Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and Matsubara H: MiR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 127:2804–2814. 2010. View Article : Google Scholar : PubMed/NCBI
27	Yamamoto H, Kohashi K, Fujita A and Oda Y: Fascin-1 overexpression and miR-133b downregulation in the progression of gastrointestinal stromal tumor. Mod Pathol. 26:563–571. 2013. View Article : Google Scholar : PubMed/NCBI